News

EFSA publishes GMO data
Enlarge image

RegulatoryEUFranceItaly

EFSA publishes GMO data

17.01.2013 - In the controversy over the harmlessness of GM maize, the EU food watchdog EFSA has published all data from its safety assessment of Monsanto’s NK603.

The EFSA’s move was triggered by „the level of public interest“ after Caen-based researcher Gilles-Eric Séralini claimed Monsanto’s GM maize NK603 harmed the health of lab rats in an experimental setting last September. However, researchers all over the world challenged Seralini’s findings saying his data were insufficient and would require publication of the raw data. 

Up to now, the scientific head of the GMO-sceptic organisation Criigen refused to do so. But in a press conference at the European Parliament Séralini announced he will publish his data now as the EFSA opened up its data first.  The EFSA, which reviews the use and authorisation of GM crops and foodstuffs, in November rejected a report by Seralini which linked NK603 to cancer found in laboratory rats as failing to meet “acceptable scientific standards.“ The EFSA decision is part of a major initiative designed to facilitate access to data, enhancing transparency in risk assessment. “Risk assessment is an evolving science and EFSA is always willing to review its past work should new robust science bring a new perspective to any of the Authority’s previous findings, „ said EFSA chief Catherine Geslain-Lanéelle.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/efsa-publishes-gmo-data.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014